9 Sources of evidence considered by the committee
The following documentation and opinion were made available to the committee:
Assessment Report prepared by the NHS Centre for Reviews and Dissemination, University of York. An update of a rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced ovarian cancer, March 2002.
Manufacturer/sponsor submissions:
-
Bristol-Myers Squibb.
Professional/specialist and patient group submissions:
-
CancerBACUP
-
Ovacome
-
Marie Curie Cancer Care
-
MRC Clinical Trials
-
National Cancer Research Institute (formerly UKCCCR)
-
Royal College of Obstetricians and Gynaecologists
External expert and patient advocate submissions:
-
Dr Martin Gore, Consultant Oncologist, Royal Marsden Hospital, London
-
Dr Ganesan, Consultant Medical Oncologist, ICRF Medical Oncology Unit, Oxford Radcliffe Hospital, Oxford
-
Louise Bayne, Chair, Ovacome
-
Martin Ledwick, Senior Cancer Information Specialist, CancerBACUP
-
Joanne Rule, Chief Executive, CancerBACUP